HEPA — Hepion Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $5.92m
- -$5.50m
- 17
- 33
- 18
- 12
Annual cashflow statement for Hepion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.72 | -20.4 | -32.7 | -42.2 | -48.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.223 | 2.53 | 6.98 | 4.01 | 5.41 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.755 | 1.63 | -5.57 | 3.15 | 2.97 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -7.57 | -16.2 | -31.2 | -35 | -40.9 |
| Capital Expenditures | -0.051 | -0.088 | -0.13 | -0.016 | -0.014 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.002 | 0 | 0.002 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.051 | -0.086 | -0.13 | -0.014 | -0.014 |
| Financing Cash Flow Items | 0 | — | — | -2 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.7 | 43.1 | 82 | -5.14 | 4.49 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.1 | 26.8 | 50.6 | -40.2 | -36.4 |